Home Nav
Nextech Invest Logo

Paul Workman

Alfred Scheidegger

Paul Workman PhD DSc (Hon) FRS FMedSci FSB FRSC is the Chief Executive and President of The Institute of Cancer Research (ICR) in London UK. He is also Harrap Professor of Pharmacology and Therapeutics and Director of the Cancer Research UK (CRUK) Centre at the ICR and Royal Marsden and Director of ICR/Imperial College Cancer Research Centre of Excellence focusing on convergence science. From 1997 to 2016 Dr Workman was Head of the ICR’s Division of Cancer Therapeutics and Director of the CRUK Cancer Therapeutics Unit – the world’s largest academic cancer drug discovery centre which has discovered 20 drug candidates since 2005. He has been elected a Fellow of the Royal Society, Fellow of the Academy of Medical Sciences, Fellow of the Royal Society of Medicine, Fellow of the Society of Biology, Fellow of the Royal Society of Chemistry and Fellow of the European Academy of Cancer Sciences, and he is CRUK Life Fellow. He was formerly Biology Section Head of Cancer Research, AstraZeneca Ltd. Dr Workman was also the scientific founder of two oncology biotech companies (Chroma Therapeutics and Piramed Pharma) and has served as a consultant to many others. As a world-leading pharmacologist and chemical biologist, Dr Workman has won numerous awards for his discovery and development of new cancer drugs and chemical probes. He recieved the 2010 Royal Society of Chemistry George and Christine Sosnovsky Award for Cancer Therapy, 2012 Royal Society of Chemistry World Entrepreneur of the Year Award, 2013 Cancer Research UK Translational Cancer Research Prize and 2014 International Raymond Bourgine Award for Excellence in Cancer Research.  Dr Workman led the team that won the 2012 American Association of Cancer Research Team Science Award and under his leadership the ICR was awarded a 2017 Queens’ Anniversary Prize for its world-leading research in cancer drug discovery leading to global patient impact.


Personalized Oncology 2019 conference

23.06. – 25.06.2019

Basel, Switzerland

  • 24.07.2019

    Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives...

  • 18.07.2019

    Blueprint Medicines Announces European Medicines Agency...

  • 15.07.2019

    Neon Therapeutics ’ Personal Neoantigen Vaccine Study...


Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.


* Compulsory fields


Newsletter Registration

Your eMail have been successfully registered.